# Korean Post-marketing Surveillance for Xeljanz

> **NCT02984020** · — · COMPLETED · sponsor: **Pfizer** · enrollment: 1041 (actual)

## Conditions studied

- Rheumatoid Arthritis
- Psoriatic Arthritis

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT02984020
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2016-05-13
- **Primary completion:** 2022-06-09
- **Final completion:** 2022-06-09
- **Target enrollment:** 1041 (ACTUAL)
- **Last updated:** 2024-08-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02984020

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02984020, "Korean Post-marketing Surveillance for Xeljanz". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02984020. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*